ArticleAnnals of internal medicine2016

Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.

Charles B Eaton MdPubMed ↗Publisher ↗

No numbers read from the abstract.